文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

急诊科流感感染合并急性呼吸衰竭患者无创通气失败的危险因素

Risk factors for non-invasive ventilation failure in influenza infection with acute respiratory failure in emergency department.
PubMed 文献 · Am J Emerg Med · 2020-09-06
一句话结论流感合并急性呼吸衰竭行无创通气者,SOFA评分、PaO2/FiO2比值及胸片浸润象限数是NIV失败的预测因素。

单因素及多因素logistic分析显示SOFA评分(P=0.001)、PaO2/FiO2比值(P=0.001)及胸片浸润象限数(P=0.001)是NIV失败的危险因素;三者预测NIV失败的AUROC分别为0.894(95%CI 0.839-0.948)、0.828(95%CI 0.764-0.892)、0.792(95%CI 0.721-0.863),三者预测能力无显著差异。PaO2/FiO2比值联合胸片浸润象限数显示出更高的NIV失败预测能力。

要点

  • 在急诊科因流感感染合并急性呼吸衰竭使用NIV的成人患者中,NIV失败率为44%(72/162)。
  • SOFA评分、PaO2/FiO2比值及胸片浸润象限数是NIV失败的独立危险因素(均P=0.001)。
  • SOFA评分预测NIV失败的AUROC为0.894(95%CI 0.839-0.948),PaO2/FiO2比值AUROC为0.828(95%CI 0.764-0.892),胸片浸润象限数AUROC为0.792(95%CI 0.721-0.863),三者无显著差异。
  • PaO2/FiO2比值联合胸片浸润象限数对NIV失败的预测能力高于单一参数。

适用人群与场景

  • 急诊科(ED)场景中,年龄>18岁、因流感感染合并急性呼吸衰竭而使用无创通气(NIV)的患者。
  • 研究排除标准原文未提及。

诊断标准与关键阈值

  • SOFA评分、PaO2/FiO2比值及胸片浸润象限数用于预测NIV失败;原文未给出具体的诊断界值或启动/停止阈值。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及具体的红旗征或需立刻处理的情况。

研究设计与关键结果

  • 研究类型为回顾性队列观察研究,单中心(Ramathibodi急诊科),样本量162例,NIV失败72例(44%)。
  • 多因素logistic分析显示SOFA评分(P=0.001)、PaO2/FiO2比值(P=0.001)、胸片浸润象限数(P=0.001)是NIV失败的危险因素。
  • SOFA评分预测NIV失败的AUROC为0.894(95%CI 0.839-0.948),PaO2/FiO2比值AUROC为0.828(95%CI 0.764-0.892),胸片浸润象限数AUROC为0.792(95%CI 0.721-0.863),三者预测能力无显著差异。
  • PaO2/FiO2比值联合胸片浸润象限数显示出更高的NIV失败预测能力(原文未提供具体数值或95%CI)。

证据类型、等级与局限

  • 证据类型:回顾性队列观察研究。
  • 原文未述局限性。

对床旁实践的改变

  • 在急诊科对流感感染合并急性呼吸衰竭患者使用NIV时,可计算SOFA评分、PaO2/FiO2比值及评估胸片浸润象限数以预测NIV失败风险;原文未提及基于这些预测因素的具体临床决策建议。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: Non-invasive ventilation (NIV) has been widely used in hypoxemic acute respiratory failure (ARF) due to influenza pneumonia in the emergency department (ED). However, NIV used in influenza-associated acute respiratory failure had a variable rate of failure. Previous studies have reported that prolonged use of NIV was associated with increased mortality. Our study aimed to identify risk factors for NIV failure in influenza infection with acute respiratory failure in ED.

METHOD: We performed a retrospective cohort observational study. Enrolled patients were older than 18 years who used NIV due to influenza infection with ARF between 1 January 2017 to 31 December 2018 in Ramathibodi Emergency Department. Patients characteristics, comorbidity, clinical, laboratory outcome, chest imaging, initial NIV setting, and parameters were collected in ED setting. Sequential organ failure assessment (SOFA) score and PaO2/FiO2 (PF) ratio were calculated from the first arterial blood gas in ED. We followed the outcome success or failure of the NIV used.

RESULTS: A total of 162 patients were enrolled and 72 (44%) suffered NIV failure in influenza infection with ARF. We used univariate and multivariate logistic analyses to assess risk factors for NIV failure. The ability of risk factor to predict NIV failure was analyzed using the area under the receiver operating characteristic (AUROC). Risk factors of NIV failure included SOFA score (P = 0.001), PF ratio (P = 0.001) and quadrant infiltrations in chest x-rays (CXR) (P = 0.001). SOFA score, PF ratio, and number quadrant infiltrations in chest radiography have good ability to predict NIV failure, AUROC 0.894 (95%CI 0.839-0.948), 0.828 (95%CI 0.764-0.892), and 0.792 (95%CI 0.721-0.863), respectively and no significant difference in the ability to predict NIV failure among three parameters. The use of PF ratio plus number quadrant infiltrations in chest radiography demonstrated a higher predictive ability for NIV failure in influenza infection with ARF.

CONCLUSIONS: SOFA score, PF ratio, and quadrant infiltrations in chest radiography were good predictors of NIV failure in influenza infection with ARF.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Suttapanit K, Boriboon J, Sanguanwit P, et al. Risk factors for non-invasive ventilation failure in influenza infection with acute respiratory failure in emergency department. Am J Emerg Med. 2020. PMID: 33041144. doi:10.1016/j.ajem.2020.08.094

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。